FI117925B - Farmaseuttinen valmiste, jossa on plasminogeeniaktivaattoreita - Google Patents

Farmaseuttinen valmiste, jossa on plasminogeeniaktivaattoreita Download PDF

Info

Publication number
FI117925B
FI117925B FI963251A FI963251A FI117925B FI 117925 B FI117925 B FI 117925B FI 963251 A FI963251 A FI 963251A FI 963251 A FI963251 A FI 963251A FI 117925 B FI117925 B FI 117925B
Authority
FI
Finland
Prior art keywords
pharmaceutical
preparation
enligt
preparation according
att
Prior art date
Application number
FI963251A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963251A0 (fi
FI963251A (fi
Inventor
Heinrich Woog
Ulrich Kohnert
Stephan Fischer
Hans-Joerg Markl
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of FI963251A0 publication Critical patent/FI963251A0/fi
Publication of FI963251A publication Critical patent/FI963251A/fi
Application granted granted Critical
Publication of FI117925B publication Critical patent/FI117925B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI963251A 1994-02-21 1996-08-20 Farmaseuttinen valmiste, jossa on plasminogeeniaktivaattoreita FI117925B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4405426A DE4405426A1 (de) 1994-02-21 1994-02-21 Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
DE4405426 1994-02-21
EP9500596 1995-02-18
PCT/EP1995/000596 WO1995022347A1 (de) 1994-02-21 1995-02-18 Pharmazeutisches präparat enthaltend plasminogenaktivatoren

Publications (3)

Publication Number Publication Date
FI963251A0 FI963251A0 (fi) 1996-08-20
FI963251A FI963251A (fi) 1996-08-20
FI117925B true FI117925B (fi) 2007-04-30

Family

ID=6510724

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963251A FI117925B (fi) 1994-02-21 1996-08-20 Farmaseuttinen valmiste, jossa on plasminogeeniaktivaattoreita

Country Status (26)

Country Link
US (1) US5747030A (no)
EP (1) EP0746334B1 (no)
JP (1) JP3868997B2 (no)
KR (1) KR100356934B1 (no)
CN (1) CN1170591C (no)
AT (1) ATE205091T1 (no)
AU (1) AU691881B2 (no)
BR (1) BR9506840A (no)
CA (1) CA2183755C (no)
CZ (1) CZ286682B6 (no)
DE (2) DE4405426A1 (no)
DK (1) DK0746334T3 (no)
ES (1) ES2162913T3 (no)
FI (1) FI117925B (no)
HU (1) HU219769B (no)
MX (1) MX9603515A (no)
NO (1) NO317726B1 (no)
NZ (1) NZ281607A (no)
PL (1) PL181257B1 (no)
PT (1) PT746334E (no)
RU (1) RU2155067C2 (no)
SG (1) SG50567A1 (no)
SK (1) SK282827B6 (no)
TW (1) TW337997B (no)
WO (1) WO1995022347A1 (no)
ZA (1) ZA951371B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
KR101378194B1 (ko) 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US11666532B2 (en) * 2018-01-19 2023-06-06 Hyloris Developments Sa Tranexamic acid oral solution
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
AU2021325324A1 (en) * 2020-08-10 2023-02-23 Chiesi Farmaceutici S.P.A. Tissue plasminogen activator formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung

Also Published As

Publication number Publication date
PT746334E (pt) 2002-02-28
CZ243196A3 (en) 1997-01-15
NZ281607A (en) 1997-04-24
KR970701059A (ko) 1997-03-17
TW337997B (en) 1998-08-11
CN1141592A (zh) 1997-01-29
PL315978A1 (en) 1996-12-23
CN1170591C (zh) 2004-10-13
HU219769B (hu) 2001-07-30
DE4405426A1 (de) 1995-08-24
NO963460D0 (no) 1996-08-20
JPH09511495A (ja) 1997-11-18
PL181257B1 (pl) 2001-06-29
HU9602284D0 (en) 1996-10-28
MX9603515A (es) 1997-03-29
NO317726B1 (no) 2004-12-13
AU1758195A (en) 1995-09-04
SK107996A3 (en) 1997-04-09
DE59509580D1 (de) 2001-10-11
EP0746334A1 (de) 1996-12-11
CZ286682B6 (en) 2000-06-14
FI963251A0 (fi) 1996-08-20
ES2162913T3 (es) 2002-01-16
EP0746334B1 (de) 2001-09-05
WO1995022347A1 (de) 1995-08-24
AU691881B2 (en) 1998-05-28
HUT74843A (en) 1997-02-28
SK282827B6 (sk) 2002-12-03
DK0746334T3 (da) 2001-12-27
SG50567A1 (en) 1998-07-20
CA2183755A1 (en) 1995-08-24
NO963460L (no) 1996-10-18
RU2155067C2 (ru) 2000-08-27
CA2183755C (en) 2004-02-17
FI963251A (fi) 1996-08-20
KR100356934B1 (ko) 2003-02-26
ZA951371B (en) 1996-08-20
JP3868997B2 (ja) 2007-01-17
US5747030A (en) 1998-05-05
BR9506840A (pt) 1997-10-14
ATE205091T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
FI117925B (fi) Farmaseuttinen valmiste, jossa on plasminogeeniaktivaattoreita
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
US6204036B1 (en) Stable transglutaminase preparations and processes for their production
JP5784907B2 (ja) 組換え型ｖｗｆ製剤
JP5253501B2 (ja) 安定化トロンビン組成物
ES2409032T3 (es) Formulaciones liofilizadas de vwf recombinante
US20010031721A1 (en) Highly concentrated, lyophilized, and liquid factor IX formulations
JP2010513462A (ja) 第ＶＩＩおよび第ＶＩＩａ因子組成物
RU2790262C2 (ru) Композиции, содержащие глюкоцереброзидазу и изофагомин
AU738891B2 (en) Stable transglutaminase preparations and process for producing them

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

FG Patent granted

Ref document number: 117925

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: ACTAVIS GROUP PTC EHF.

Free format text: ACTAVIS GROUP PTC EHF.

MM Patent lapsed